RGRN-305
Phase 2- Indications
- Psoriasis, Hidradenitis suppurativa
Company intelligence / Profile preview
Regranion, LLC
Mount Pleasant/Charleston, South Carolina, United Statesregranion.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Regranion’s lead product, RGRN‑305, is an orally delivered small molecule HSP90 inhibitor that has shown broad-spectrum anti-inflammatory activity and clinical safety/efficacy in patients with autoimmune skin diseases such as psoriasis and hidradenitis suppurativa. The company reports no specific organ toxicity or consistent hematology/biochemistry changes in trials. Other pipeline assets are at the preclinical stage.
- Therapeutic areas
- DermatologyCardiovascularImmunology
- Modalities
- Small moleculesSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Regranion, LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regranion, LLC.